Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
…, A Sundin, ET Janson, S Welin, D Granberg… - Clinical Cancer …, 2007 - AACR
Purpose: A retrospective analysis of the toxicity and efficacy of temozolomide in advanced
neuroendocrine tumors. Experimental Design: Thirty-six patients with advanced stages of …
neuroendocrine tumors. Experimental Design: Thirty-six patients with advanced stages of …
Treatment with cisplatin and etoposide in patients with neuroendocrine tumors
MLH Fjällskog, DPK Granberg… - … Journal of the …, 2001 - Wiley Online Library
BACKGROUND Patients with malignant endocrine pancreatic tumors (EPTs) are
responsive to combinations of chemotherapy with streptozotocin and 5‐fluorouracil/doxorubicin, …
responsive to combinations of chemotherapy with streptozotocin and 5‐fluorouracil/doxorubicin, …
Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment
…, U Garske-Román, D Granberg… - Journal of Nuclear …, 2013 - Soc Nuclear Med
The organs at risk in radionuclide therapy with 177 Lu-octreotate are the bone marrow and
the kidneys. The primary aim of this study was to develop an individualized dosimetry …
the kidneys. The primary aim of this study was to develop an individualized dosimetry …
[HTML][HTML] Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility …
…, H Lundqvist, B Eriksson, A Sundin, D Granberg - European journal of …, 2018 - Springer
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with
advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-…
advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-…
Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE
…, B Eriksson, D Granberg… - Journal of nuclear …, 2015 - Soc Nuclear Med
Peptide receptor radionuclide therapy (PRRT) is a promising treatment for patients with
neuroendocrine tumors, giving rise to improved survival. Dosimetric calculations in relation to …
neuroendocrine tumors, giving rise to improved survival. Dosimetric calculations in relation to …
Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
M Sandström, U Garske, D Granberg, A Sundin… - European journal of …, 2010 - Springer
Purpose In recent years, targeted radionuclide therapy with [ 177 Lu-DOTA 0 , Tyr 3 ]octreotate
for neuroendocrine tumours has yielded promising results. This therapy may be further …
for neuroendocrine tumours has yielded promising results. This therapy may be further …
Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification
…, H Lundqvist, D Granberg… - Journal of Nuclear …, 2014 - Soc Nuclear Med
Quantitative imaging and dosimetry are crucial for individualized treatment during peptide
receptor radionuclide therapy (PRRT). Lu-DOTATATE and 68 Ga-DOTATOC/ 68 Ga-…
receptor radionuclide therapy (PRRT). Lu-DOTATATE and 68 Ga-DOTATOC/ 68 Ga-…
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
EA Carlsen, N Fazio, D Granberg… - Endocrine-related …, 2019 - erc.bioscientifica.com
Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic
neuroendocrine tumors grade 1–2 (G1–G2). However, its possible benefit in high-grade …
neuroendocrine tumors grade 1–2 (G1–G2). However, its possible benefit in high-grade …
Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors
…, J Sörensen, B Eriksson, D Granberg… - Journal of Nuclear …, 2013 - Soc Nuclear Med
68 Ga-DOTATOC and 68 Ga-DOTATATE are 2 radiolabeled somatostatin analogs for in vivo
diagnosis of neuroendocrine tumors with PET. The aim of the present work was to measure …
diagnosis of neuroendocrine tumors with PET. The aim of the present work was to measure …
Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs
S Singh, D Granberg, E Wolin, R Warner… - Journal of global …, 2017 - ascopubs.org
Purpose Despite the considerable impact of neuroendocrine tumors (NETs) on patients’
daily lives, the journey of the patient with a NET has rarely been documented, with published …
daily lives, the journey of the patient with a NET has rarely been documented, with published …